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Abstract
Background: N-myristoylation is a crucial covalent modification of numerous eukaryotic and viral proteins that is catalyzed
by N-myristoyltransferase (NMT). Prokaryotes are lacking endogeneous NMT activity. Recombinant production of N-
myristoylated proteins in E. coli cells can be achieved by coexpression of heterologous NMT with the target protein. In the
past, dual plasmid systems were used for this purpose.
Methodology/Principal Findings: Here we describe a single vector system for efficient coexpression of substrate and
enzyme suitable for production of co- or posttranslationally modified proteins. The approach was validated using the HIV-1
Nef protein as an example. A simple and efficient protocol for production of highly pure and completely N-myristoylated
Nef is presented. The yield is about 20 mg myristoylated Nef per liter growth medium.
Conclusions/Significance: The single vector strategy allows diverse modifications of target proteins recombinantly
coexpressed in E. coli with heterologous enzymes. The method is generally applicable and provides large amounts of
quantitatively processed target protein that are sufficient for comprehensive biophysical and structural studies.
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Introduction
N-myristoylation is the covalent attachment of myristic acid to an
NH2-terminal glycine residue of a protein substrate via an amide
bond [1]. The reaction is catalyzed by N-myristoyltransferase
(NMT), an essential enzyme of 50 to 60 kDa that is ubiquitously
expressed in many organisms [2]. Following the discovery of N-
myristoylation by Carr et al. [3] numerous N-myristoylated
eukaryotic and viral proteins have been identified (reviewed in
[1,4]). Myristoylated proteins play key roles, for example in
oncogenesis, cell signaling and infectivity of retroviruses.
Protein myristoylation has been linked to various biological
functions. It is involved in membrane binding and targeting.
Suppression of N-myristoylation can adversely affect the subcel-
lular location of proteins. For example, myristoylated Gag
precursor polyprotein of the spleen necrosis virus is anchored in
the plasma membrane during proteolytic cleavage. In contrast,
nonmyristoylated Gag mutants undergo aberrant processing
resulting in failure of virus particle assembly and release [5]. N-
myristoylation can have a strong impact on protein structure [6],
e.g. it confers structural and thermal stability to the catalytic
subunit of cAMP-dependent protein kinase [7,8]. Thus, proteins
that require such modification for biologic activity should be
studied in their myristoylated form. Large amounts of functional
protein, however, are often required for structural and biophysical
studies. The most widely employed organism for recombinant
protein production is E. coli. Often, this allows biosynthesis of
diverse proteins at high yield and low cost. A major drawback of
protein expression in bacterial hosts is the absence of eukaryote-
specific co- and posttranslational modifications, e.g. due to lack of
endogenous NMT activity.
Several alternatives are available for N-myristoylation of
bacterially expressed proteins. Successful in vitro myristoylation
on an analytical scale has been reported [9,10]. Catalytic amounts
of exogeneous NMT, protein substrate, and an excess of myristic
acid are incubated during the reaction. Even though almost
quantitative in vitro N-myristoylation of a 17 kDa protein has been
observed after 8 hours of incubation, the reaction rate and
efficiency appears to decrease with increasing size of the protein
substrate [9]. Both the NMT and the target protein must be
purified prior to the in vitro myristoylation and an additional
purification step is necessary to remove the enzyme, unmodified
protein and the fatty acid substrate after the reaction.
Higher yields of N-myristoylated proteins can be achieved by
coexpression of target proteins with a heterologous N-myristoyl-
transferase in E. coli [11–17]. In cell N-myristoylation is triggered
by supplementing the growth medium with the NMT substrate
myristic acid. In the past, dual plasmid systems have been
employed, where one plasmid carries an NMT gene while the
other one codes for the target protein. Stable maintenance of both
plasmids in the same cell, however, requires the use of two vectors
with compatible replicons and different antibiotic resistance
markers.
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The ratio of codons present in the coding sequence of a
heterologous gene product frequently proves inconsistent with the
tRNA pool of E. coli (codon bias). Thus, the limited supply of
certain tRNAs in E. coli often impedes efficient production of
heterologous proteins especially from organisms with AT- and
GC-rich genomes. Modified bacterial strains are available to
overcome this problem. They contain an additional plasmid which
encodes tRNAs that tend to get depleted during expression of the
target gene. However, maintenance of the additional plasmid
requires a distinct antibiotic resistance marker. Transformation of
such an E. coli strain with two plasmids for expression of NMT and
target protein, respectively, would therefore result in a system that
subjects the host cell to three separate antibiotics. Exposure to
multiple antibiotics further increases the level of stress on the
bacterium and a reduced target protein yield is often observed.
The situation may become even worse if isotope labeling of the
target protein is desired necessitating bacterial growth and gene
expression in minimal medium. The number of antibiotic
resistance markers can be reduced either by optimizing codon
selection in the gene of the target protein or by using a single
vector with two expression cassettes in tandem for production of
the NMT and the target protein. In the first case, the additional
plasmid for production of rare tRNAs is no longer needed.
Equally, the use of a bicistronic vector instead of two plasmids
reduces the number of required antibiotic resistance markers by
one.
Nef is an accessory protein of approximately 25 kDa encoded in
the genome of human immunodeficiency virus 1 (HIV-1). It is a
multifunctional protein that plays a crucial role in HIV
pathogenesis and in disease progression to AIDS (e.g. reviewed
in [18–21]) and is therefore target of vaccination studies [22]. Nef
enhances viral replication and accelerates the immune evasion of
infected cells by manipulating transport as well as signaling
pathways [23–27]. Nef-induced modulation of cellular signaling
and transport pathways results in altered surface expression of cell
surface receptors like CD4 and major histocompatibility complex
class I and II or chemokine receptors [25,28–32]. Also,
interactions of Nef with components of the host cell cytoskeleton
are documented that lead to rearrangements during e.g. the
immunological synapse formation [33]. The majority of these Nef
activities require a membrane localization of the protein that is
supported by its N-myristoylation [34,35].
We used the single vector system pETDuet-1 (Novagen) for
cloning and coexpression of HIV-1 nef and human N-myristoyl-
transferase (hNMT-1) genes. For production of both proteins the
pETDuet-1 recombinant was transferred to E. coli BL21-
CodonPlus(DE3)-RIL competent cells (Stratagene) containing
extra copies of the argU, ileY and leuW tRNA genes for improved
translation efficiency of AT-rich heterologous proteins. Our
strategy avoids the need for a time- and sometimes cost-intensive
codon optimization of the gene of the myristoylation target
without increasing the number of antibiotic resistance markers
beyond two. High yield production and efficient purification of
completely myristoylated Nef is demonstrated. The proposed
strategy presents a general and highly efficient way for production
of heterologous N-myristoylated proteins in E. coli.
Results and Discussion
High-yield production of N-myristoylated Nef
Vectors pETDuet-1D6His_hNMT_Nef and pETDuet-1D6His_
Nef were used for expressions of the nef gene with and without
subsequent myristoylation of Nef, respectively. High-level produc-
tion of Nef in BL21-CodonPlus(DE3)-RIL cells after induction with
IPTG is demonstrated by SDS-PAGE traces in Figure 1. An
additional, less intense but clearly visible band arises after induction
of cells transformed with pETDuet-1D6His_hNMT_Nef (Figure 1
B). This additional band runs at a height corresponding to the
molecular weight of 48.1 kDa of hNMT(81–496), indicating
successful coexpression of the truncated N-myristoyltransferase.
The molecular weight of Nef (24641 Da) and myristoylated Nef
(24851 Da) differs by less than 1%, resulting in virtually
indistinguishable running behavior in SDS-PAGE (see Figure 1).
Proof of successful myrstoylation of Nef was obtained from ESI-MS
analysis (see below).
Each of the two expression cassettes in the bicistronic vector
pETDuet-1 contains its own T7lac transcription promoter and a
ribosome binding site. However, there is only one transcription
Figure 1. SDS-PAGE of cells expressing Nef (A) or myristoylated Nef (myr.Nef) resulting from coexpression of Nef and hNMT (B).
Aliquots of the expression cultures were taken before as well as 1.5 and 5 hours after IPTG induction. The corresponding lanes are labeled with ‘‘B’’,
‘‘1.5’’ and ‘‘5’’, respectively. In addition, protein molecular weight marker (‘‘M’’) was applied.
doi:10.1371/journal.pone.0010081.g001
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terminator site located downstream of MCS2. Assuming that
genes 1 and 2 had been cloned into the MCS1 and MCS2 sites of
pETDuet-1, respectively, transcription should yield two different
mRNAs. A shorter one is initiated at the T7 promoter
immediately preceding gene 2 and a longer one is initiated at
the promoter upstream of gene 1. Both transcripts should
terminate downstream of gene 2. Thus, it can be expected that
translation of gene 1 will occur exclusively from the bicistronic
mRNA while gene 2 will be translated from both the short and
long transcripts [36]. The significantly higher yield of Nef in
comparison to hNMT(81–496) observed in the pETDuet-
1D6His_hNMT_Nef expression (Figure 1 B) is in perfect
agreement with the expectations. Interestingly, bicistronic vectors
containing two target genes under the control of a single promoter
that precedes both genes frequently show strongly reduced
expression of the gene located more distant from the promoter
site in comparison with a two promoter vector [37].
Purification of both Nef and myristoylated Nef was accom-
plished with a straightforward and efficient protocol. The His-
tagged Nef protein was isolated on a Ni-NTA affinity matrix
followed by enzymatic removal of the His tag by overnight
incubation with GST-PreScission protease during dialysis. The
GST-tagged protease, cleaved His tag, and His-tagged Nef fusion
were removed from the target protein Nef employing GSH and
Ni-NTA affinity columns prior to the final polishing step on a size
exclusion chromatography (SEC) column.
An overlay of the SEC profiles documenting the final
purification step of Nef and N-myristoylated Nef, respectively, is
shown in Figure 2. The maxima of the main peaks elute at the
same volume in both runs and the elution volume indicates
monomeric Nef. The two small peaks eluting at 44 and 51 ml
contain minor fractions of aggregated protein and GST-PreScis-
sion protease, respectively. SDS-PAGE analysis of the SEC
fractions collected after applying myristoylated Nef to the column
revealed virtually pure Nef in fractions 57 through 73 (Figure 3).
The tail trailing of the main peak in case of myristoylated Nef
obviously represents a more compact conformation in comparison
with the major component. Breuer et al. proposed that the elution
peak of myristoylated Nef reflects the coexistence of two molecular
shapes - the acyl chain might be exposed in the ‘‘open’’ state, but
inserted in a hydrophobic cavity in the ‘‘closed’’ or ‘‘compact’’
state [12]. Such a model was proposed earlier [38], and later it was
shown that Nef indeed binds its own myristoylated amino-
terminus [39]. In contrast, the elution peak of unmodified Nef is
narrower and does likely reflect a single molecular shape. The
observed behavior is reminiscent of the ‘‘myristoyl switch’’
mechanism - a conformational change that exposes or sequesters
the myristoyl chain - which has been described for other
myristoylated proteins [1,2,40,41]. Very recently, a ‘‘myristoyl
switch’’ mechanism driven by a combination of electrostatic
attraction and membrane curvature sensing was proposed based
on comprehensive Nef membrane binding data [42].
Complete myristoylation of Nef
High purity of the obtained myristoylated Nef was confirmed by
ESI mass spectrometry. A single component with a molecular
weight of 24849 Da was detected, which is in agreement with the
theoretical value (24851 Da). Figure 4 shows a section of the mass
spectrum. There were no indications on the presence of any
unmyristoylated Nef (calculated molecular weight 24641 Da) in
the mass spectrometry data, supporting that myristoylation was
virtually complete.
The NH2-terminal amino acid sequence of Nef matches the
consensus sequence of NMT protein substrates: Met-Gly-X-X-X-
Ser/Thr-Lys/Arg-. The initiating Met is removed cotranslation-
ally by methionine amino peptidase and Gly becomes the NH2-
terminal amino acid. In general, N-myristoylation of proteins in
mammalian cells occurs cotranslationally on the ribosome.
Notably, NH2-terminally truncated hNMT lacking the ribosome
targeting sequence retains in vitro catalytic activity [43]. Addition-
ally it is known that the use of full length hNMT occasionally can
result in rather incomplete myristoylation of the substrate [16].
General applicability of the approach
Although coexpression of substrate and enzyme by a bicistronic
vector has been shown before [44,45] this is, to the best of our
Figure 2. Gel filtration chromatograms documenting the final
purification step of Nef and myristoylated Nef (myr. Nef).
Protein samples were loaded onto a preparative HiLoad 16/60 Superdex
75 column, eluted with a flow rate of 1 ml/min and the absorbance at
280 nm was recorded. The elution profiles with maxima of the main
peaks at around 61 ml indicate a monomeric state of Nef. Minor
fractions eluting at around 44 and 51 ml reflect traces of aggregated
protein and GST-PreScission protease, respectively.
doi:10.1371/journal.pone.0010081.g002
Figure 3. SDS-PAGE of 2 ml fractions collected during the final
gel filtration of myristoylated Nef. Aliquots of the SEC fractions of
myristoylated Nef (cf. Figure 2) were applied on a 15% SDS
polyacrylamide gel followed by coomassie staining. SDS-PAGE revealed
virtually pure Nef. Lanes are labeled with the elution volumes of the
analyzed aliquots (57–71). Protein bands of the applied molecular
weight marker (M) are labeled with the corresponding molecular
weight in kDa.
doi:10.1371/journal.pone.0010081.g003
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knowledge, the first report on efficient production of a myristoy-
lated protein in E. coli utilizing a bicistronic vector. The pETDuet-
1 vector was originally designed for production and analysis of
protein-protein complexes but also allows co/post-translational
modification of heterologous proteins. The nef gene was inten-
tionally cloned into MCS2 while the gene encoding the enzyme
was inserted into MCS1. As expected, this resulted in a
significantly higher yield of Nef in comparison to the enzyme (cf.
Figure 1 B). Importantly, the amount of active hNMT was
sufficient for complete myristoylation of Nef. Our simple and
efficient protocol resulted in ,20 mg purified N-myristoylated Nef
per liter of expression culture. This will allow continuation of the
structural characterization of Nef complexes with other proteins
[46–51] in a native like membrane environment.
Breuer et al. employed the more common dual vector strategy
in combination with a codon optimized nef gene for high-yield
production (,30 mg protein per liter) of N-myristoylated Nef [12].
However, this increased yield required codon optimization of the
gene coding for the protein of interest whereas our novel approach
avoids this additional effort without increasing the overall number
of required antibiotics. Moreover, only one instead of two
transformation steps is needed.
The major advantage of our strategy is that only one antibiotic
is required for stable maintenance of the single vector coding for
both the enzyme NMT and the substrate Nef. The second
antibiotic employed in our protocol allows convenient protein
expression in cell lines that contain an extra plasmid for
production of rare tRNAs. However, a second antibiotic is not
required for expression of the dual vector in standard BL21
competent cells. In fortunate cases, the two original target genes
will express at high levels in standard BL21 competent cells.
Alternatively, codon-optimized genes may be utilized to boost
expression in such cells without the need for a second antibiotic. In
contrast, the dual vector strategy with separate plasmids for
substrate and enzyme always requires a minimum of two different
antibiotics. Further, use of the bicistronic vector with two
transcription promoter and ribosome binding sites but only one
transcription terminator site allowed us to channel the bacterial
resources mainly towards production of the target protein Nef
while only a small but sufficient amount of enzyme was produced.
Finally, the use of a single instead of two plasmids for expression of
substrate and enzyme eliminates the potential problem of
incompatible ORIs that may arise in two plasmid systems.
In summary, the single vector based strategy demonstrated here
for the expression of N-myristoylated HIV-1 Nef in E. coli offers a
simple, general, easy to use, straightforward and efficient
alternative to the previously described dual plasmid systems.
Materials and Methods
Vector preparation and cloning
The dual gene expression vector pETDuet-1 (Novagen) carries
the pBR322-derived ColE1 replicon, the lacI gene, the ampicillin
resistance gene, and two multiple cloning sites MCS1 and MCS2.
Each of the two MCS is preceded by a T7lac promoter and a
ribosome binding sequence. First, we removed the sequence
coding for the NH2-terminal hexahistidine (His) tag of the gene
product in the MCS1 cassette by cleavage of the original
pETDuet-1 plasmid with restriction endonucleases NcoI and
EcoRI, followed by blunt-end ligation. The resulting vector is
referred to as pETDuet-1D6His in what follows.
The nef gene of HIV-1 isolate SF2 (SwissProt accession no.
P03407) was PCR-amplified from the previously described vector
pUbi-Nef2–210 [39] using primers containing the NdeI and MunI
restriction sites at the 59 and 39 ends, respectively. The 39 primer
represents the reverse complement of the nucleotide sequence
coding for the last seven COOH-terminal amino acid residues of
Nef, the PreScission protease cleavage site (LEVLFQGP), a His
affinity tag and a stop-codon followed by the MunI site. The
amplified nef gene was cloned into MCS2 of the modified
pETDuet-1 vector utilizing the NdeI and MunI sites. The obtained
vector pETDuet-1D6His_Nef was employed for production of
nonmyristoylated Nef.
A gene coding for residues 81 to 496 of human N-
myristoyltransferase (hNMT-1) was PCR-amplified from the vector
pBB218 [52] and cloned into MCS1 of the pETDuet-1D6His_Nef
vector between the EcoRI and HindIII restriction sites. NH2-
terminally truncated hNMT(81–496) is catalytically active but
lacks the ribosome binding site of the full length protein [43]. The
resulting vector pETDuet-1D6His_hNMT_Nef was used for
production of N-myristoylated Nef. All enzymes required for
cloning were obtained from Fermentas (St. Leon-Rot, Germany).
Protein expression and purification
E. coli strain BL21-CodonPlus(DE3)-RIL (Stratagene) was
transformed with plasmid pETDuet-1D6His_Nef or pETDuet-
1D6His_hNMT_Nef. Recombinant protein production was per-
formed in LB medium supplemented with ampicillin (100 mg/ml)
and chloramphenicol (34 mg/ml). Each 1 l expression medium was
inoculated with an aliquot of a 50 ml overnight culture to an
optical density of ,0.1 at 600 nm (OD600). After the culture had
reached an OD600 of 0.6 the temperature was reduced from 37uC
to 28uC. Gene expression was induced at an OD600 of 0.8 by
addition of a 1 M isopropyl-b-D-thiogalactopyranosid (IPTG)
stock solution to a final concentration of 0.5 mM. For production
of N-myristoylated Nef the hNMT substrate myristic acid (Sigma,
Seelze, Germany) was added 10 min before induction to a final
concentration of 50 mM. Myristic acid was supplied as a freshly
prepared 5 mM stock solution containing 0.6 mM BSA (Sigma).
The pH of the stock solution was adjusted with NaOH to 9 and
briefly heated to 50uC for complete solubilization of myristic acid.
Cells were incubated under gentle agitation (150 rpm) and
harvested 5 hours after induction by centrifugation (5000 6 g,
4uC, 30 min). Cell pellets were washed in 16 PBS buffer, spun
Figure 4. Section of mass spectrum of myristoylated Nef.
Electrospray ionization mass spectrometry confirmed the successful
myristoylation of Nef. Notably, no unmyristoylated Nef could be
detected. The experimentally determined molecular weight of 24849 Da
is in accordance with the theoretical value of 24851 Da.
doi:10.1371/journal.pone.0010081.g004
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down and stored at -20uC. Protein expression was checked by
SDS-PAGE.
For protein purification cell pellets harvested from 1 l culture
volume were thawn and resuspended on ice in 25 ml lysis buffer
(20 mM Tris-HCl pH 8.0, 500 mM NaCl, 20 mM imidazole
pH 8.0, 15 mM b-mercaptoethanol) supplemented with lysozyme
(200 mg/ml) and protease inhibitor cocktail (Complete, EDTA-
free; Roche). Cells were disrupted by sonification on ice using a
Branson 250 sonifier equipped with a microtip (3 cycles of 30 s
with 1.5 min of cooling on ice in between). The crude lysate was
clarified by centrifugation (500006 g, 4uC, 30 min). Subsequent
purification steps were performed at 6uC ambient temperature.
The supernatant was applied onto a gravity flow column (column
volume (CV) of 5 ml) packed with nickel-nitrilotriacetic acid (Ni-
NTA) agarose (Qiagen; Hilden, Germany) and pre-equilibrated
with lysis buffer. Unbound material was removed by washing with
10 CV of lysis buffer followed by 10 CV of lysis buffer containing
30 mM imidazole. Nef or myristoylated Nef protein, respectively,
bound via the His tag, was eluted by increasing the imidazole
concentration in the buffer. Nef containing fractions were pooled
and dialyzed against 20 mM Tris-HCl pH 8.0, 500 mM NaCl,
15 mM b-mercaptoethanol. The His tag was enzymatically
removed with glutathion-S-transferase (GST)-tagged PreScission
protease (GE Healthcare, Freiburg) during dialysis. Cleavage/
dialysis was performed overnight utilizing ,1 mg of protease per
5 mg of Nef. Separation of the His tag, any uncleaved His-tagged
Nef fusion protein and the GST-tagged PreScission protease from
untagged Nef protein was accomplished with two gravity columns
(CV of 5 ml each) in series. The first column was packed with
GSH-Sepharose 4 B (GE Healthcare) and the second one with Ni-
NTA agarose. Nef containing flow-through fractions were
combined and applied to a HiLoad 16/60 Superdex 75 prep
grade column (GE Healthcare) pre-equilibrated with 20 mM Tris-
HCl pH 8.0, 150 mM NaCl, 15 mM b-mercaptoethanol. The gel
filtration column was operated on an A¨KTA purifier system at
10uC with a flow rate of 1 ml/min. Protein sizes were estimated
based on a column calibration with a mixture of low molecular
weight proteins (gel filtration calibration kit LMW; GE Health-
care). Nef containing fractions were pooled and concentrated with
centriprep devices (Millipore). Cleavage, separation efficiency and
final purity were evaluated by SDS-PAGE analysis. Nef solution
was kept at 4uC for short-term storage or shock frozen in liquid
nitrogen prior to long-term storage at 280uC.
Electrospray ionization (ESI) mass spectrometry
Purity and myristoylation efficiency of the acylated Nef was
checked by ESI mass spectrometry. Prior to analysis with an ESI-
QqTOF instrument (QSTAR XL; Applied Biosystems, Darm-
stadt) low molecular weight buffer components were removed on a
reverse phase column (Resource RPC 1 ml; GE Healthcare)
operated with a linear gradient from 100% buffer A (100%
ddH2O, 0.1% (v/v) TFA) to 100% buffer B (80% acetonitrile,
20% ddH2O, 0.08% (v/v) TFA) over 20 column volumes. MS
analysis was performed at the BMFZ core facility of the University
of Du¨sseldorf.
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